{"id":"quillivant-xr","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Decreased appetite"},{"rate":"15-25","effect":"Insomnia"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Abdominal pain"},{"rate":"5-15","effect":"Nervousness"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Increased blood pressure"}]},"_chembl":{"chemblId":"CHEMBL258896","moleculeType":"Small molecule","molecularWeight":"549.67"},"_dailymed":{"setId":"c2dc2109-44a6-4797-b04e-18761dd9d45a","title":"QUILLIVANT XR (METHYLPHENIDATE HYDROCHLORIDE) SUSPENSION, EXTENDED RELEASE [NEXTWAVE PHARMACEUTICALS, INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate is a central nervous system stimulant that works by blocking the reuptake of dopamine and norepinephrine at the presynaptic neuron, increasing their availability in the synaptic cleft. The extended-release formulation provides sustained drug delivery throughout the day, allowing for once-daily dosing in patients with ADHD. This sustained elevation of catecholamines enhances focus, attention, and impulse control while reducing hyperactive and impulsive behaviors.","oneSentence":"Quillivant XR is an extended-release formulation of methylphenidate that increases dopamine and norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:28.709Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Methylphenidate","title":"Methylphenidate","extract":"Methylphenidate, sold under the brand name Ritalin and Concerta, among others, is a central nervous system (CNS) stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It may be taken by mouth or applied to the skin, and different formulations have varying durations of effect. For ADHD, the effectiveness of methylphenidate is comparable to atomoxetine but modestly lower than amphetamine. However, methylphenidate is preferred as a first-line treatment in children, while amphetamine is preferred in adults. Methylphenidate reduces core ADHD symptoms and may do so in part by enhancing executive functions, such as working memory, sustained attention, and inhibitory control."},"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"}]},"trialDetails":[{"nctId":"NCT07314333","phase":"PHASE1","title":"A Trial to Assess How Centanafadine Interacts With Stimulants in the Body","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-02-05","conditions":"ADHD","enrollment":42},{"nctId":"NCT01628029","phase":"PHASE2","title":"Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-01-15","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder","enrollment":68},{"nctId":"NCT07300956","phase":"PHASE4","title":"Treating Young Children With Attention Deficit Hyperactivity Disorder","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2026-02","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":370},{"nctId":"NCT05916339","phase":"PHASE4","title":"AWARE: Management of ADHD in Autism Spectrum Disorder","status":"RECRUITING","sponsor":"Daniel Coury","startDate":"2023-10-01","conditions":"ADHD, Autism Spectrum Disorder","enrollment":500},{"nctId":"NCT04419272","phase":"PHASE4","title":"Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-08-14","conditions":"Epilepsy","enrollment":226},{"nctId":"NCT03420339","phase":"PHASE4","title":"Stimulant Effects on Disruptive Behavior","status":"RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2018-10-01","conditions":"Attention Deficit Hyperactivity Disorder, Problem Behavior","enrollment":10},{"nctId":"NCT04219280","phase":"PHASE4","title":"Evaluating Treatment of ADHD in Children with Down Syndrome","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2020-10-02","conditions":"Down Syndrome, ADHD","enrollment":100},{"nctId":"NCT05650775","phase":"PHASE1","title":"Biomarkers of ADHD Treatment Response","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2023-02-17","conditions":"ADHD","enrollment":16},{"nctId":"NCT02096952","phase":"PHASE4","title":"Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-05","conditions":"Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder","enrollment":15},{"nctId":"NCT04987762","phase":"PHASE4","title":"Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children","status":"TERMINATED","sponsor":"Purdue Pharma LP","startDate":"2021-08-03","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":103},{"nctId":"NCT04507204","phase":"PHASE4","title":"Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"TERMINATED","sponsor":"Purdue Pharma LP","startDate":"2020-07-30","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":267},{"nctId":"NCT02683265","phase":"PHASE4","title":"A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-04-25","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":158},{"nctId":"NCT02327195","phase":"PHASE1","title":"General Anesthesia Emergence Induced by Methylphenidate","status":"COMPLETED","sponsor":"Nicoleta Stoicea","startDate":"2014-05","conditions":"Delayed Emergence From Anesthesia","enrollment":54},{"nctId":"NCT02470234","phase":"PHASE4","title":"Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-07-30","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":10},{"nctId":"NCT04152629","phase":"PHASE4","title":"Real World Evidence of the Efficacy and Safety of FOQUEST","status":"COMPLETED","sponsor":"Purdue Pharma, Canada","startDate":"2019-09-19","conditions":"Attention Deficit-Hyperactivity Disorder","enrollment":257},{"nctId":"NCT00429273","phase":"PHASE4","title":"Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2007-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":212},{"nctId":"NCT04138498","phase":"PHASE1, PHASE2","title":"CTx-1301 Comparative Bioavailability Study","status":"COMPLETED","sponsor":"Cingulate Therapeutics","startDate":"2019-12-06","conditions":"ADHD","enrollment":45},{"nctId":"NCT02210728","phase":"NA","title":"Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder","status":"UNKNOWN","sponsor":"Lily Hechtman","startDate":"2006-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":200},{"nctId":"NCT02788851","phase":"NA","title":"The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-04","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":70},{"nctId":"NCT02566824","phase":"PHASE4","title":"Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2010-10","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":216},{"nctId":"NCT01835548","phase":"PHASE3","title":"NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Neos Therapeutics, Inc","startDate":"2013-07","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":87},{"nctId":"NCT02255565","phase":"PHASE4","title":"Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2014-09","conditions":"ADHD, Autism","enrollment":36},{"nctId":"NCT00393042","phase":"PHASE3","title":"Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2006-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":77},{"nctId":"NCT01133847","phase":"PHASE4","title":"Interventions for Children With Attention and Reading Disorders","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2010-11","conditions":"Attention Deficit Hyperactivity Disorder, Reading Disabilities","enrollment":222},{"nctId":"NCT02677519","phase":"PHASE4","title":"A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD","status":"UNKNOWN","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":120},{"nctId":"NCT00904670","phase":"PHASE3","title":"Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":45},{"nctId":"NCT00069927","phase":"PHASE2","title":"Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression","status":"TERMINATED","sponsor":"University of South Florida","startDate":"2003-08","conditions":"Depression, Neurotoxicity, Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":12},{"nctId":"NCT00593138","phase":"PHASE1, PHASE2","title":"Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-12","conditions":"Drug Binding to DAT Receptors","enrollment":23},{"nctId":"NCT00889915","phase":"PHASE4","title":"Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-04","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":228},{"nctId":"NCT00323947","phase":"PHASE4","title":"Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2003-05","conditions":"Attention Deficit Disorder With Hyperactivity, Epilepsy","enrollment":33},{"nctId":"NCT00564954","phase":"PHASE4","title":"A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-10","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":86},{"nctId":"NCT00776009","phase":"PHASE4","title":"Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":165},{"nctId":"NCT00141063","phase":"PHASE3","title":"Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"ADHD","enrollment":90},{"nctId":"NCT00141050","phase":"PHASE3","title":"Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-05","conditions":"ADHD","enrollment":90}],"_emaApprovals":[],"_faersSignals":[{"count":503,"reaction":"DRUG INEFFECTIVE"},{"count":165,"reaction":"ABNORMAL BEHAVIOUR"},{"count":163,"reaction":"OFF LABEL USE"},{"count":148,"reaction":"DECREASED APPETITE"},{"count":118,"reaction":"DRUG EFFECT INCOMPLETE"},{"count":102,"reaction":"AGGRESSION"},{"count":93,"reaction":"PRODUCT USE ISSUE"},{"count":83,"reaction":"FEELING ABNORMAL"},{"count":80,"reaction":"DISTURBANCE IN ATTENTION"},{"count":78,"reaction":"PSYCHOMOTOR HYPERACTIVITY"}],"_approvalHistory":[{"date":"20170104","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20120927","type":"ORIG","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20160513","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20150713","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20260309","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20131212","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20130515","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20231013","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20160527","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20170124","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20150417","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20210625","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20130809","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"},{"date":"20250923","type":"SUPPL","sponsor":"NEXTWAVE","applicationNumber":"NDA202100"}],"publicationCount":69,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["methylphenidate hydrochloride oral suspension"],"phase":"marketed","status":"active","brandName":"Quillivant XR","genericName":"Quillivant XR","companyName":"Children's Hospital Medical Center, Cincinnati","companyId":"children-s-hospital-medical-center-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Quillivant XR is an extended-release formulation of methylphenidate that increases dopamine and norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}